Want to see TSE:NLH full AI Analyst Report?
Nova Leap Health (NLH) AI Stock Analysis
Nova Leap Health
(TSXV:NLH)
The score is driven primarily by improving (but still inconsistent) financial performance—profitability has returned and leverage is conservative, but margins and cash conversion remain uneven. Technical signals are a meaningful positive with price above key moving averages and positive momentum indicators, partially offset by near-overbought stochastic readings. Valuation is a modest headwind given the P/E level and lack of dividend support in the provided data.
Nova Leap Health (NLH) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 43.66M
- Dividend Yield
- ―
- Average Volume (3M)
- 21.13K
- Price to Earnings (P/E)
- 23.5
- Beta (1Y)
- 0.31
- Revenue Growth
- 18.35%
- EPS Growth
- 1021.05%
- Country
- Canada
- Employees
- 541
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Care Facilities
Nova Leap Health Business Overview & Revenue Model
Company Description
Nova Leap Health Corp. delivers a comprehensive array of in-home and healthcare-at-home solutions across the United States and Canada. Their offerings encompass specialized dementia support, social companionship, assistance with personal needs, and t...
Nova Leap Health Financial Statement Overview
Summary
Income statement quality is improving with a return to profitability and modest revenue growth, supported by steady gross margin and positive operating results. However, net margins remain thin and multi-year earnings have been volatile, while cash flow conversion/coverage has been inconsistent despite positive operating and free cash flow. The balance sheet is a key strength with conservative leverage, partially offset by only moderate ROE.
Income Statement
62PositiveBalance Sheet
74PositiveCash Flow
56Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.23M | 32.02M | 25.76M | 26.18M | 28.21M | 21.28M |
| Gross Profit | 12.94M | 11.85M | 9.89M | 9.77M | 9.98M | 7.21M |
| EBITDA | 2.71M | 1.97M | 2.50M | 1.35M | 420.35K | 4.76M |
| Net Income | 1.32M | -193.19K | 1.38M | -1.05M | -835.75K | 1.76M |
Balance Sheet | ||||||
| Total Assets | 25.75M | 23.44M | 22.39M | 20.90M | 23.95M | 26.77M |
| Cash, Cash Equivalents and Short-Term Investments | 1.44M | 1.49M | 1.40M | 894.76K | 1.27M | 1.73M |
| Total Debt | 4.45M | 2.93M | 2.53M | 1.40M | 3.97M | 6.20M |
| Total Liabilities | 6.37M | 4.43M | 4.14M | 2.70M | 5.27M | 8.29M |
| Stockholders Equity | 19.39M | 19.01M | 18.25M | 18.20M | 18.68M | 18.48M |
Cash Flow | ||||||
| Free Cash Flow | 1.95M | 1.42M | 1.36M | 2.13M | 949.49K | 2.18M |
| Operating Cash Flow | 1.91M | 1.42M | 1.39M | 2.15M | 1.02M | 2.18M |
| Investing Cash Flow | -2.25M | -1.26M | -1.59M | -23.13K | -56.24K | -7.40M |
| Financing Cash Flow | 388.04K | -86.91K | 729.78K | -2.52M | -1.41M | 4.33M |
Nova Leap Health Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:NLH, the sentiment is Positive. The current price of 0.50 is above the 20-day moving average (MA) of 0.47, below the 50-day MA of 0.51, and above the 200-day MA of 0.40, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 55.75 is Neutral, neither overbought nor oversold. The STOCH value of 82.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:NLH.
Nova Leap Health Peers Comparison
Overall Rating
TSE:CRRX74Outperform
TSE:EXE73Outperform- TSE:NLH68Neutral
TSE:DR62Neutral
TSE:SIA56Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| TSE:CRRX | 74Outperform | CAD 213.86M | 7.86 | 25.79% | 2.43% | 2.96% | ― |
| TSE:EXE | 73Outperform | CAD 2.53B | 20.13 | 36.33% | 1.96% | 31.14% | 34.48% |
| TSE:NLH | 68Neutral | CAD 43.66M | 23.54 | 6.95% | ― | 18.35% | 1021.05% |
| TSE:DR | 62Neutral | CAD 237.42M | 8.20 | 45.36% | 2.45% | 2.64% | -56.04% |
| TSE:SIA | 56Neutral | CAD 2.18B | 37.83 | 6.58% | 4.76% | 16.11% | 31.75% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:NLH | Nova Leap Health | 0.50 | 0.22 | 78.57% | |
| TSE:CRRX | Carerx Corporation | 3.37 | -0.05 | -1.40% | |
| TSE:EXE | Extendicare Inc. | 26.57 | 10.57 | 66.03% | |
| TSE:SIA | Sienna Senior Living | 19.67 | 1.39 | 7.57% | |
| TSE:DR | Medical Facilities Corp | 14.68 | 0.56 | 3.95% |
Nova Leap Health Corporate Events
Nova Leap to Spotlight Record Quarter and Growth Strategy at Planet MicroCap Showcase
PositiveNova Leap Health Corp. will showcase its record second-quarter performance and growth strategy at the Planet MicroCap Showcase in Toronto later this month. President and CEO Chris Dobbin is scheduled to deliver a webcast presentation on October 28, f...
Nova Leap Health Delivers Record Q2 Results and Accelerates Home Care Expansion
PositiveNova Leap Health Corp. reported record financial results for the second quarter of 2026, with revenue rising 17.1% year over year to $9.39 million and trailing twelve-month revenue reaching $33.6 million, the highest in the company’s history. A...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 17, 2026